A Phase 1b/2 Study of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients With Advanced Gastrointestinal Malignancies (HERKULES-3)
Latest Information Update: 08 Jul 2024
At a glance
- Drugs Cetuximab (Primary) ; Encorafenib (Primary) ; ERAS 007 (Primary) ; Palbociclib (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Gastrointestinal cancer; Pancreatic cancer
- Focus Adverse reactions; Proof of concept
- Acronyms HERKULES-3
- Sponsors Erasca
- 04 Jun 2024 Results (n=19; as of 30 Nov 2023) reporting updated data presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 17 May 2024 According to an Erasca media release, the company deprioritized ERAS-007 as clinical efficacy data (data to be presented at ASCO 2024) do not support continued evaluation.
- 08 May 2024 According to a Erasca media release, phase 1b combination data expected in the second quarter of 2024.